EDP Biotech Corp. and New Day Diagnostics LLC are merging to form a vertically integrated force in the expedited development and commercialization of diagnostic tests.

EDP Biotech Corp.和New Day Diagnostics LLC正在合并，以在诊断测试的快速开发和商业化中形成垂直整合的力量。

The strategic union brings together EDP Biotech's position as an established and growing specialty diagnostic developer and contract research organization (CRO) with New Day Diagnostics' pipeline of diversified diagnostic tests and commercialization capabilities.

战略联盟汇集了EDP Biotech作为一家成熟且不断发展的专业诊断开发商和合同研究组织（CRO）的地位，拥有New Day Diagnostics多元化诊断测试和商业化能力的渠道。

The pair aim to empower patients through affordable access to diagnostic testing, thereby leading to earlier intervention. By combining their complementary expertise and resources, EDP Biotech and New Day Diagnostics intend to establish a company capable of improving patient lives through diagnostics offerings. The newly formed entity will act as an innovator throughout the entire diagnostic process, from biomarker discovery to product launch.

这对夫妇的目标是通过负担得起的诊断测试来增强患者的能力，从而导致更早的干预。通过结合他们互补的专业知识和资源，EDP Biotech和New Day Diagnostics旨在建立一家能够通过诊断产品改善患者生活的公司。从生物标志物发现到产品发布，新成立的实体将在整个诊断过程中充当创新者。

Leveraging vertical integration and strategic partnerships, the merged company will have the ability to design, develop, and deploy diagnostic tests.  .

利用垂直整合和战略合作伙伴关系，合并公司将有能力设计，开发和部署诊断测试。 .

'We are thrilled to announce our merger with New Day Diagnostics,' said EDP Biotech Corp. CEO Eric Mayer, who will be president and chief executive of the merged organization. 'This strategic marriage will allow us to continue delivering diagnostic solutions, making an impact on patient care and outcomes including the under-served population and uninsured patients.'  .

EDP生物技术公司首席执行官Eric Mayer说：“我们很高兴宣布与New Day Diagnostics的合并。”这场战略性婚姻将使我们能够继续提供诊断解决方案，从而影响患者的护理和结果，包括服务不足的人群和未投保的患者 。.

EDP Biotech Corp. currently develops ColoPlex, an aid in diagnosis for detecting colorectal cancers and polyps early, and serves a growing roster of diagnostic companies with its full-service CRO focused on in-vitro diagnostics (IVD), development, testing, and commercialization. The company operates a CLIA lab providing business-to-business and direct-to-consumer testing, multiplex assays, research, and validation services.  .

EDP Biotech Corp.目前开发ColoPlex，这是一种早期检测结直肠癌和息肉的诊断辅助工具，为越来越多的诊断公司名册提供服务，其全方位CRO专注于体外诊断（IVD），开发，测试和商业化。该公司运营一个CLIA实验室，提供企业对企业和直接面向消费者的测试，多重分析，研究和验证服务。 。.

The Boca Raton-based New Day Diagnostics brings a diversified pipeline of physician point-of-care and physician mediated-direct-to-consumer (DTC) tests to the combined entity. These include a first-to-market DTC celiac disease test and additional offerings targeting infectious diseases, ovarian cancer, and prostate cancer.  .

基于Boca Raton的新日间诊断为组合实体带来了多样化的医生护理点和医生介导的直接面向消费者（DTC）测试管道。这些包括首次销售DTC乳糜泻测试和针对传染病，卵巢癌和前列腺癌的其他产品。 。.

Together, EDP Biotech and New Day Diagnostics are set to capitalize on the changing patient dynamics in the diagnostics industry. By leveraging their combined development capabilities, distribution channels, and strategic partnerships, the merged entity will have the ability to address multiple indications, transforming the way patients access and benefit from diagnostic testing.

EDP Biotech和New Day Diagnostics共同利用诊断行业不断变化的患者动态。通过利用其综合开发能力，分销渠道和战略合作伙伴关系，合并后的实体将能够解决多种适应症，改变患者访问和受益于诊断测试的方式。

.

.

'By joining forces with EDP Biotech, we are strengthening our position as a leading provider of fast, accurate, and affordable diagnostic tests,' said New Day Diagnostics Founder/CEO Navroze Mehta, who will serve as executive chairman of the new company. 'Together, we will pioneer advancements in diagnostic testing, improving patient lives through early detection and intervention.'   .

“通过与EDP Biotech的合作，我们正在加强我们作为快速，准确和经济实惠的诊断测试的领先供应商的地位，”New Day Diagnostics创始人/首席执行官Navroze Mehta说，他将担任新公司的执行主席我们将共同开创诊断测试的进步，通过早期发现和干预改善患者生活  。.

The newly merged entity will retain the name New Day Diagnostics, and both companies' teams will be headquartered in Knoxville, Tenn. The merger is subject to customary closing conditions and regulatory approvals.

新合并的实体将保留New Day Diagnostics的名称，两家公司的团队将总部设在田纳西州诺克斯维尔。合并受制于习惯性结束条件和监管部门的批准。

TCB Capital Advisors, an affiliate of Weild & Co, acted as the exclusive financial advisor to EDP Biotech on this transaction, and Brock Shipe Klenk PLC and Merchant & Gould acted as EDP Biotech’s legal advisors and Cuenot, and PAG Law PLLC and Forsythe & Kim LLC acted as New Day’s legal advisors.   .

Weild＆Co的子公司TCB资本顾问担任EDP Biotech在此交易中的独家财务顾问，Brock Shipe Klenk PLC和Merchant＆Gould担任EDP Biotech的法律顾问和Cuenot，PAG Law PLLC和Forsythe＆Kim LLC担任New Day的法律顾问。 。.

EDP Biotech Corporation, incorporated in 2005, is a privately held ISO 13485:2016 and CLIA certified in-vitro diagnostics laboratory specializing in early detection biomarker assay development and commercialization, diagnostic and companion CRO services, and clinical patient and community testing in oncology, infectious disease, and women’s health.

EDP生物技术公司于2005年注册，是一家私营的ISO 13485:2016和CLIA认证的体外诊断实验室，专门从事早期检测生物标志物检测开发和商业化，诊断和伴随CRO服务以及肿瘤学临床患者和社区检测，传染病和妇女健康。

EDP Biotech's founding was in oncology biomarkers.  .

EDP Biotech的成立是在肿瘤学生物标志物。 。.

Based in Boca Raton, Fla., New Day Diagnostics develops diagnostic solutions that lead to improved patient outcomes while reducing health care costs. New Day is in active development of affordable state-of-the-art rapid, point-of-care tests that allow early detection and monitoring of disease through accuracy, ease of use, and speed, facilitating treatment. .

位于佛罗里达州博卡拉顿的New Day Diagnostics开发了诊断解决方案，可以在降低医疗保健成本的同时改善患者预后。新的一天正在积极开发负担得起的最先进的快速即时检验，通过准确性，易用性和速度早期发现和监测疾病，促进治疗。。.

TCB Capital Advisors specializes in advising on companies' buying, selling, investment, and growth strategies. TCB Capital Advisors is an affiliate of Weild & Co. Securities transactions effected through Weild & Co., member FINRA/SIPC.

TCB资本顾问专门为公司的购买，销售，投资和增长策略提供建议。TCB资本顾问是Weild＆Co.通过Weild＆Co.，成员FINRA/SIPC进行的证券交易的子公司。